{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:22:16Z","timestamp":1777724536171,"version":"3.51.4"},"reference-count":84,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"The High Commission for Scientific Research (HCSR) in Syria"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>The effect of pre-hospital use of renin\u2013angiotensin system (RAS) inhibitors (angiotensin-converting enzyme inhibitors (ACEis)\/angiotensin receptor blockers (ARBs)) on clinical outcomes of hypertensive patients with COVID-19 has been questioned due to conflicting reports on this issue. After applying exclusion criteria, 175 COVID-19 hospitalized patients admitted to the Tishreen Hospital from January 1 to July 31, 2021 were retrospectively enrolled in this study. Baseline characteristics and in-hospital mortality rate were assessed between hypertensive (N\u2009=\u200991, 52%) and non-hypertensive (N\u2009=\u200984, 48%) patients, as well as between patients taking ACEis\/ARBs and non-ACEis\/ARBs within the hypertensive group. A lower mortality rate (51.2 versus 31.9%, p\u2009=\u20090.009) was observed in the hypertensive group (mean age 64.6\u2009years, 64.8% males) compared to the non-hypertensive (mean age 62.6\u2009years, 66.7% males). Patients\u2019 mortality in the non-hypertensive group was associated with lower blood oxygen saturation (SPO2\u2009=\u200975 versus 86%, p\u2009=\u20090.002), increased levels of inflammatory (CRP, white blood cell and neutrophils count), and tissue\/renal injury markers (LDH, urea, and creatinine). In the hypertensive group, a lower mortality rate was noted in the ACEis\/ARBs group compared to the non-ACEis\/ARBs (24.1 versus 45.5%, p\u2009=\u20090.036), and this was associated with a decrease in D-DIMER levels, although not significant (1723 versus 2683\u2009ng\/mL, p\u2009&gt;\u20090.05). Death in the non-ACEis\/ARBs group was associated with decreased SPO2 and tissue\/renal injury markers (LDH, CK, AST, urea, and creatinine). We concluded that hypertension is not a direct cause of poor prognosis in COVID-19 patients and that multi-organ damage is a significant indicator of death from COVID-19. RAS inhibitors could improve the survival of hypertensive COVID-19 patients.<\/jats:p>","DOI":"10.1177\/10815589241270417","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:15:45Z","timestamp":1722298545000},"page":"863-875","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["The effect of pre-hospital use of RAS inhibitors on COVID-19 mortality"],"prefix":"10.1177","volume":"72","author":[{"given":"Rama","family":"Ibrahim","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Microbiology, Faculty of Pharmacy,Al-Sham Private University (ASPU), Lattakia, Syria"},{"name":"Department of Biochemistry and Microbiology, Faculty of Pharmacy, Tishreen University, Lattakia, Syria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.588013"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2020.0502"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14657"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.16667"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)12323-7"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy439"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.917"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22713-z"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.11.032"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002450"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01275-w"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.2357"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-04956-y"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-020-0279-4"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12159"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.5471"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-020-0455-8"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-021-09663-z"},{"issue":"3","key":"e_1_3_3_24_2","first-page":"302","article-title":"Lessons from SARS: a new potential therapy for acute respiratory distress syndrome (ARDS) with angiotensin converting enzyme 2 (ACE2)","volume":"57","author":"Imai Y","year":"2008","unstructured":"Imai Y, Kuba K, Penninger JM. Lessons from SARS: a new potential therapy for acute respiratory distress syndrome (ARDS) with angiotensin converting enzyme 2 (ACE2). Masui 2008; 57(3): 302\u2013310.","journal-title":"Masui"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.2174\/18735592MTEwFNzYF3"},{"issue":"21","key":"e_1_3_3_26_2","first-page":"e017736","article-title":"Mortality and pre-hospitalization use of renin-angiotensin system inhibitors in hypertensive COVID-19 patients","volume":"9","author":"Chen C","year":"2020","unstructured":"Chen C, Wang F, Chen P, et al. Mortality and pre-hospitalization use of renin-angiotensin system inhibitors in hypertensive COVID-19 patients. J Am Heart Assoc 2020; 9(21): e017736.","journal-title":"J Am Heart Assoc"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/0036933020949219"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1746200"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15143"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.3594"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.4480"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026143"},{"key":"e_1_3_3_33_2","doi-asserted-by":"crossref","first-page":"e072175","DOI":"10.1136\/bmj-2022-072175","article-title":"Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial","volume":"379","author":"Jardine MJ","year":"2022","unstructured":"Jardine MJ, Kotwal SS, Bassi A, et al. Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ 2022; 379: e072175.","journal-title":"BMJ"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1080\/10641963.2020.1783549"},{"key":"e_1_3_3_35_2","article-title":"Burden and prevalence of risk factors for severe COVID-19 disease in the ageing European population\u2014a SHARE-based analysis","author":"Ahrenfeldt LJ","year":"2020","unstructured":"Ahrenfeldt LJ, Nielsen CR, Moller S, et al. Burden and prevalence of risk factors for severe COVID-19 disease in the ageing European population\u2014a SHARE-based analysis. Res Sq 2020.","journal-title":"Res Sq"},{"key":"e_1_3_3_36_2","first-page":"247","article-title":"Prevalence of comorbidities in COVID-19 patients: a systematic review and meta-analysis","volume":"8","author":"Baradaran A","year":"2020","unstructured":"Baradaran A, Ebrahimzadeh MH, Baradaran A, et al. Prevalence of comorbidities in COVID-19 patients: a systematic review and meta-analysis. Arch Bone Jt Surg 2020; 8(Suppl 1): 247\u2013255.","journal-title":"Arch Bone Jt Surg"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-33314-9"},{"issue":"1","key":"e_1_3_3_38_2","first-page":"e72","article-title":"The prevalence of underlying diseases and comorbidities in COVID-19 patients; an updated systematic review and meta-analysis","volume":"8","author":"Khateri S","year":"2020","unstructured":"Khateri S, Mohammadi H, Khateri R, et al. The prevalence of underlying diseases and comorbidities in COVID-19 patients; an updated systematic review and meta-analysis. Arch Acad Emerg Med 2020; 8(1): e72.","journal-title":"Arch Acad Emerg Med"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.923485"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.5888\/pcd18.210123"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2349890"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02156-9"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001116"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100158"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40292-022-00506-9"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-01134-5"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41440-022-00893-5"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.120.15324"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002666"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14038"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02902-w"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30165-X"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14522"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14429"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-82862-5"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41556-024-01388-w"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-021-11579-x"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.15276"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0191-2022"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857573"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365513.2020.1768587"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246087"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2021.11.012"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1855"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-022-01207-3"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.734917"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.25864"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1080\/10641963.2020.1764018"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023535"},{"key":"e_1_3_3_70_2","volume-title":"D Dimer","author":"Bounds EJ","unstructured":"Bounds EJ, Kok SJ. D Dimer. Treasure Island, FL: StatPearls Publishing LLC, 2022."},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14768"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12864"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-020-01769-9"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14859"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.repc.2021.06.021"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41371-020-00405-3"},{"issue":"5","key":"e_1_3_3_77_2","first-page":"1847","article-title":"High expression of angiotensin-converting enzyme 2 receptor (ACE-2), transmembrane protease serine (TMPRSS), and P-selectin in platelets lead to thrombosis formation in COVID-19 patients","volume":"28","author":"Waggiallah HA","year":"2024","unstructured":"Waggiallah HA, Eltayeb MM, Hjazi AM, et al. High expression of angiotensin-converting enzyme 2 receptor (ACE-2), transmembrane protease serine (TMPRSS), and P-selectin in platelets lead to thrombosis formation in COVID-19 patients. Eur Rev Med Pharmacol Sci 2024; 28(5): 1847\u20131856.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2020.1822737"},{"issue":"1","key":"e_1_3_3_79_2","first-page":"34","article-title":"Acute kidney failure in patients admitted due to COVID-19","volume":"41","author":"Tarragon B","year":"2021","unstructured":"Tarragon B, Valdenebro M, Serrano ML, et al. Acute kidney failure in patients admitted due to COVID-19. Nefrologia 2021; 41(1): 34\u201340.","journal-title":"Nefrologia"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.500"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201439"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200652"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-020-02324-z"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3COVR0520-272R"},{"key":"e_1_3_3_85_2","article-title":"Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19","author":"Zuo Y","year":"2020","unstructured":"Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps (NETs) as markers of disease severity in COVID-19. medRxiv 2020.","journal-title":"medRxiv"}],"container-title":["Journal of Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589241270417","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10815589241270417","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589241270417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:40:10Z","timestamp":1777459210000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10815589241270417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1177\/10815589241270417"],"URL":"https:\/\/doi.org\/10.1177\/10815589241270417","relation":{},"ISSN":["1081-5589","1708-8267"],"issn-type":[{"value":"1081-5589","type":"print"},{"value":"1708-8267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,28]]}}}